WP 1074
Alternative Names: Birch pollen allergy immunotherapy - Worg Pharmaceuticals; WP-1074Latest Information Update: 28 Mar 2026
At a glance
- Originator Biomay
- Developer Worg Pharmaceuticals (Hangzhou)
- Class Antiallergics; Peptide vaccines; Tree pollen allergy immunotherapies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Tree pollen hypersensitivity
Most Recent Events
- 28 Mar 2026 No recent reports of development identified for preclinical development in Tree pollen hypersensitivity in China
- 18 Feb 2022 Preclinical trials in Tree pollen hypersensitivity in China (unspecified route) (Worg Pharmaceuticals pipeline, February 2022)
- 31 Dec 2020 Worg Pharmaceuticals acquires WP 1073 from Biomay